Cargando…

Modeling early treatment response in AML from cell-free tumor DNA

Monitoring disease response after intensive chemotherapy for acute myeloid leukemia (AML) currently requires invasive bone marrow biopsies, imposing a significant burden on patients. In contrast, cell-free tumor DNA (ctDNA) in peripheral blood, carrying tumor-specific mutations, offers a less-invasi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Dantong, Rausch, Christian, Buerger, Simon A., Tschuri, Sebastian, Rothenberg-Thurley, Maja, Schulz, Melanie, Hasenauer, Jan, Ziemann, Frank, Metzeler, Klaus H., Marr, Carsten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690559/ https://www.ncbi.nlm.nih.gov/pubmed/38047080 http://dx.doi.org/10.1016/j.isci.2023.108271

Ejemplares similares

P1402: ALTERATIONS OF HUMAN BONE MARROW NICHE IN CLONAL HEMATOPOIESIS AND AML
por: Dragieva, Y., et al.
Publicado: (2022)

P457: COMPLEX CARYOTYPE IS AN INDEPENDENT RISK FACTOR IN TP53-MUTATED AML
por: Rausch, Christian, et al.
Publicado: (2023)

Progressive disruption of hematopoietic architecture from clonal hematopoiesis to MDS
por: Buck, Michèle C., et al.
Publicado: (2023)

Germline SNPs previously implicated as prognostic biomarkers do not associate with outcomes in intensively treated AML
por: Batcha, Aarif M. N., et al.
Publicado: (2022)

Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
por: Rausch, Christian, et al.
Publicado: (2023)

P434: MYELODYSPLASIA-RELATED MUTATIONS IN THE NEW ELN CLASSIFICATION: DOES CLONAL SIZE PLAY A ROLE?
por: Rausch, Christian, et al.
Publicado: (2023)

P446: COMPREHENSIVE CHARACTERIZATION OF DIFFERENTIAL GENE EXPRESSION AND ISOFORM USAGE IN SPLICING FACTOR-MUTATED ACUTE MYELOID LEUKEMIA USING LONG-READ SEQUENCING
por: Thieme, Susanne, et al.
Publicado: (2023)

Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
por: Kunadt, Desiree, et al.
Publicado: (2022)

Plasticity in growth behavior of patients’ acute myeloid leukemia stem cells growing in mice
por: Ebinger, Sarah, et al.
Publicado: (2020)

Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study
por: Middeke, Jan M., et al.
Publicado: (2022)

Explainable AI identifies diagnostic cells of genetic AML subtypes
por: Hehr, Matthias, et al.
Publicado: (2023)

Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation
por: Jentzsch, Madlen, et al.
Publicado: (2022)

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia
por: Rothenberg-Thurley, Maja, et al.
Publicado: (2018)

Loss-of-function mutations in the histone methyltransferase EZH2 promote chemotherapy resistance in AML
por: Kempf, Julia M., et al.
Publicado: (2021)

Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older
por: Prassek, Victoria V., et al.
Publicado: (2018)

Threshold-Free Population Analysis Identifies Larger DRG Neurons to Respond Stronger to NGF Stimulation
por: Andres, Christine, et al.
Publicado: (2012)

A clinically applicable gene expression–based score predicts resistance to induction treatment in acute myeloid leukemia
por: Moser, Christian, et al.
Publicado: (2021)

Mediation analysis reveals common mechanisms of RUNX1 point mutations and RUNX1/RUNX1T1 fusions influencing survival of patients with acute myeloid leukemia
por: Hornung, Roman, et al.
Publicado: (2018)

Clonal heterogeneity of FLT3-ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia
por: Schranz, Katrin, et al.
Publicado: (2018)

GAS6 expression identifies high-risk adult AML patients: potential implications for therapy
por: Whitman, Susan P., et al.
Publicado: (2013)

Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
por: Haubner, S., et al.
Publicado: (2018)

Loss of KDM6A confers drug resistance in acute myeloid leukemia
por: Stief, Sophie M., et al.
Publicado: (2019)

Nuclear factor of activated T-cells, NFATC1, governs FLT3(ITD)-driven hematopoietic stem cell transformation and a poor prognosis in AML
por: Solovey, Maria, et al.
Publicado: (2019)

Allelic Imbalance of Recurrently Mutated Genes in Acute Myeloid Leukaemia
por: Batcha, Aarif M. N., et al.
Publicado: (2019)

Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
por: Herold, Tobias, et al.
Publicado: (2020)

DNA Methylation Clusters and Their Relation to Cytogenetic Features in Pediatric AML
por: Lamba, Jatinder K., et al.
Publicado: (2020)

dsDNA from extracellular vesicles (EVs) in adult AML
por: Bernardi, Simona, et al.
Publicado: (2020)

RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade
por: Ruzicka, Michael, et al.
Publicado: (2019)

Fatty Acid Binding Protein FABP4 Mechanistically Links Obesity with Aggressive AML by Enhancing Aberrant DNA Methylation in AML Cells
por: Yan, F, et al.
Publicado: (2016)

The new and recurrent FLT3 juxtamembrane deletion mutation shows a dominant negative effect on the wild-type FLT3 receptor
por: Sandhöfer, Nadine, et al.
Publicado: (2016)

Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML
por: Tothova, Zuzana, et al.
Publicado: (2021)

IRF8 Is an AML-Specific Susceptibility Factor That Regulates Signaling Pathways and Proliferation of AML Cells
por: Liss, Franziska, et al.
Publicado: (2021)

Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia
por: Reiter, K, et al.
Publicado: (2018)

P694: RISK ASSESSMENT ACCORDING TO IPSS-M IS SUPERIOR TO AML ELN 2022 RISK CLASSIFICATION IN MDS/AML PATIENTS DEFINED BY ICC – IS AN INCLUSION INTO AML TRIALS JUSTIFIED?
por: Huber, Sandra, et al.
Publicado: (2023)

Altered expression response upon repeated gene repression in single yeast cells
por: Schuh, Lea, et al.
Publicado: (2022)

AML consolidation therapy: timing matters
por: Reimann, Adrian-Manuel, et al.
Publicado: (2023)

PU.1 downregulation in murine radiation-induced acute myeloid leukaemia (AML): from molecular mechanism to human AML
por: Verbiest, Tom, et al.
Publicado: (2015)

Compartment-specific mutational landscape of clonal hematopoiesis
por: Hartmann, Luise, et al.
Publicado: (2022)

AML1/ETO Oncoprotein Is Directed to AML1 Binding Regions and Co-Localizes with AML1 and HEB on Its Targets
por: Gardini, Alessandro, et al.
Publicado: (2008)

The role of the proteasome in AML
por: Csizmar, C M, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_00qgajg04969t6umavmtqtlug3